Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for UBRELVY™ (ubrogepant) for the acute treatment of migraine with or without aura in adults. UBRELVY™ is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start. Migraine is a neurological disease characterized by intermittent migraine attacks with symptoms that are often incapacitating. Migraine afflicts 31 million Americans and is the third most common disease and second leading cause of disability worldwide.
Approximately 12-14% of people worldwide suffer from migraine; it is a type of headache. According to the regional and international regulations, migraine is classified by the nature of the attack and the frequency becomes chronic migraine and episodic migraine. Prophylaxis and failed two treatments available to eliminate this type headaches. Prophylactic treatment offered to patients who suffer from chronic migraine to avoid a migraine attack utilizing drugs such as topiramate, botulinum toxin, and others. failed treatment offered to end a severe migraine attack and include drugs such as ergot alkaloids, triptans, and others.
Global Migraine Drugs Market is expected to reach USD 3.71 billion by 2025, from USD 2.82 billion in 2017 growing at a CAGR of 3.5% during the forecast period of 2018 to 2025.
There are numerous factors that is driving the growth of the migraine Drug market. Such as global rise in population particularly female population, inaccessibility of permanent cure, rising genericization of drugs, changing lifestyles, rising incidences of hormonal imbalance and increasing stress levels.
Among all regions, the Asia-Pacific region were considered to indicate a significant growth rate since the vendor increasing focus on emerging markets. Growth in this market is further associated with the increasing demand for better healthcare facilities and improvements in health infrastructure. In addition, this region is an exceptional opportunity for investors and venture capitalists, as an emerging market is relatively saturated. These factors tend to trigger a request for migraine market during the assessment period.
Some of the major players in the Migraine Drugs market are: Allergan, Merck, Pfizer, Teva, Pfizer, Johnson & Johnson, Endo International, GlaxoSmithKline, Impax, Abbott, Bayer, Eli Lilly, Ethypharm, Kowa Pharmaceuticals America, Winston Pharmaceuticals, AstraZeneca
Segment by Application: Hospitals, Clinics, Household Use, Others
Purchase a copy of Global Novel Oral Anticoagulants Drugs Market Report 2019 (100+Pages) @
MarketInsightsReports (An Ameliorate Solutions Group Company) provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.